Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Public ClinicalTrials.gov record NCT00942305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks. Dosing was initiated immediately following engraftment (between Days 14-30 post-transplant) to prevent/control cytomegalovirus (CMV) infection or prevent disease in R+ hematopoietic stem cell transplant (HCT) recipients.
Study identification
- NCT ID
- NCT00942305
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2009 (Actual)
- Primary completion
- Jan 2012 (Actual)
- Completion
- Jan 2012 (Actual)
- Last update posted
- Jul 16, 2021
2009 – 2012
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Winship Cancer Institute at Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Brigham and Womens Hospital, Division of Infectious Disease | Boston | Massachusetts | 02115 | — |
| University of Michigan Medical School | Ann Arbor | Michigan | 48109 | — |
| Harper University Hospital | Detroit | Michigan | 48201 | — |
| University of Minnesota Medical Center | Minneapolis | Minnesota | 55455 | — |
| Nebraska Medical Center | Omaha | Nebraska | 68198-5130 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Mt. Sinai School of Medicine | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Montefiore Medical Center Oncology | The Bronx | New York | 10467 | — |
| UNC Health Care Center | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27517 | — |
| The Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| UT Southwestern Medical Center at Dallas | Dallas | Texas | 75390-8565 | — |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Utah Cancer Specialists - Intermountain Healthcare | Salt Lake City | Utah | 84088 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00942305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2021 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00942305 live on ClinicalTrials.gov.